Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cardiac assessment before doxorubicin treatment

Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Key clinical point: Performing left ventricular ejection fraction (LVEF) measurement before doxorubicin chemotherapy may not be helpful.

Major finding: Among diffuse large B-cell lymphoma (DLBCL) patients who had LVEF measured, the incidence of heart failure post treatment did not differ between patients who received doxorubicin and those who did not (P = 1.0).

Study details: A retrospective analysis of 291 patients diagnosed with DLBCL between 2001 and 2013.

Disclosures: The researchers reported having no competing interests.

Read the article here.

Citation:

Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85.